Business Wire

Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...
Monthly Prescribing Reference

FDA Approves New Formulation of Gvoke for Severe Hypoglycemia

Credit: Getty Images. The FDA has approved the new Gvoke® Kit formulation for the treatment of severe hypoglycemia in patients with diabetes 2 years of age and older. The Food and Drug Administration ...
Nasdaq

Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above

First ready-to-use liquid glucagon available in a single-dose vial and syringe kit for rescue CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company ...
Monthly Prescribing Reference

Gvoke Kit Now Available for Severe Hypoglycemia

The new Gvoke Kit formulation is available as a 1mg/0.2mL single-dose vial and syringe kit. Gvoke ® Kit is now available for the treatment of severe hypoglycemia in adult and pediatric patients with ...